Bioengineering advances in pancreatic cancer organoids for reproducible tumor microenvironment modeling.

Renyu Chen, Bohui Yin, Yaowei Zhang, Junya Peng, Xiaoliang Guo, Wenming Wu

Abstract readReview

In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Renyu ChenDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Bohui YinDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Yaowei ZhangCollege of Information Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.

Junya PengState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.

Xiaoliang GuoSchool of Mechatronical Engineering, Beijing Institute of Technology, Beijing 100081, China.

Wenming WuDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains lethal due to late-stage diagnosis and limited non-surgical treatment options. Its intratumoral heterogeneity and desmoplastic tumor microenvironment (TME) drive invasion, immune escape, and treatment failure. Patient-derived organoids (PDOs) have emerged as efficient model platforms for simulating the TME and preserving tumor heterogeneity and enabling functional testing

Indexed as

bioengineeringbiological sciencescancer

Identifiers

PMID42389605

DOI10.1016/j.isci.2026.116487

PMCPMC13320341

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.